CSL Management

Management criteria checks 4/4

CSL's CEO is Paul McKenzie, appointed in Mar 2023, has a tenure of less than a year. total yearly compensation is $4.90M, comprised of 19.7% salary and 80.3% bonuses, including company stock and options. directly owns 0.004% of the company’s shares, worth MX$74.08M. The average tenure of the management team and the board of directors is 4.9 years and 4.5 years respectively.

Key information

Paul McKenzie

Chief executive officer

US$4.9m

Total compensation

CEO salary percentage	19.7%
CEO tenure	less than a year
CEO ownership	0.004%
Management average tenure	4.9yrs
Board average tenure	4.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Paul McKenzie's remuneration changed compared to CSL's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2022	n/a	n/a	US$2b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	US$5m	US$965k	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	n/a	n/a	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	US$6m	US$989k	US$2b
Mar 31 2021	n/a	n/a	US$3b
Dec 31 2020	n/a	n/a	US$3b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	US$7m	US$1m	US$2b

Compensation vs Market: Paul's total compensation ($USD4.90M) is about average for companies of similar size in the MX market ($USD5.70M).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.

CEO

Paul McKenzie (56 yo)

less than a year

Tenure

US$4,901,125

Compensation

Dr. Paul F. McKenzie, Ph.D. (Chemical Engineering), has been Chief Operating Officer at CSL Behring LLC since 2019. Dr. McKenzie serves as Chief Operating Officer at CSL Plasma Inc. Dr. McKenzie had been C...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Paul McKenzie	MD, CEO & Executive Director	less than a year	US$4.90m	0.0043% MX$ 74.1m
Joy Linton	Chief Financial Officer	2.1yrs	US$4.39m	0.0024% MX$ 41.3m
Paul Perreault	Strategic Advisor	less than a year	US$9.86m	0.034% MX$ 591.8m
Mark Dehring	Head of Investor Relations	no data	no data	no data
Gregory Boss	Executive VP of Legal & Group General Counsel	14.3yrs	US$2.31m	no data
Christina Hickie	Senior Manager of Communications	no data	no data	no data
Elizabeth Walker	Executive VP & Chief Human Resources Officer	5.3yrs	US$1.35m	no data
Karen Etchberger	Executive Vice President of Quality & Business Services	13yrs	US$2.14m	no data
Jemimah Brennan	Head of Communications - Asia Pacific	no data	no data	no data
William Campbell	Executive VP & Chief Commercial Officer	5.6yrs	US$2.37m	no data
Andrew Nash	Senior Vice President of Research	no data	no data	no data
William Mezzanotte	Executive VP	4.5yrs	US$2.14m	no data

4.9yrs

Average Tenure

61yo

Average Age

Experienced Management: CSL N's management team is considered experienced (4.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Paul McKenzie	MD, CEO & Executive Director	less than a year	US$4.90m	0.0043% MX$ 74.1m
Megan Clark	Independent Non Executive Director	7.2yrs	US$254.72k	0.00092% MX$ 15.9m
Alison Watkins	Independent Non-Executive Director	1.7yrs	US$190.91k	0.00067% MX$ 11.6m
Carolyn Hewson	Independent Non-Executive Director	3.3yrs	US$246.54k	0.00034% MX$ 5.9m
Brian McNamee	Independent Non-Executive Chairman	5.2yrs	US$632.01k	0.030% MX$ 524.8m
Bruce Brook	Independent Non-Executive Director	11.7yrs	US$238.62k	0.0014% MX$ 23.3m
Robert Cuthbertson	Non-Independent Non-Executive Director	4.5yrs	US$591.86k	0.019% MX$ 323.1m
Duncan Maskell	Independent Non-Executive Director	1.7yrs	US$166.31k	0.00015% MX$ 2.6m
Marie McDonald	Independent Non-Executive Director	9.7yrs	US$224.80k	0.00080% MX$ 13.8m

4.5yrs

Average Tenure

65.5yo

Average Age

Experienced Board: CSL N's board of directors are considered experienced (4.5 years average tenure).

CSL Management

Management criteria checks 4/4

Key information

Recent management updates

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

Independent Non Executive Director recently bought Mex$939k worth of stock

Recent updates

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

Independent Non Executive Director recently bought Mex$939k worth of stock

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Non-Independent Non-Executive Director recently sold Mex$87m worth of stock

Upcoming dividend of US$1.18 per share

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

Full year 2022 earnings released: EPS: US$4.81 (vs US$5.22 in FY 2021)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age